Lisa Larkin
Internal Medicine · Cincinnati, OHNPI 1679562839
Payments from drug & device makers
Across 643 payments — averaging $429.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$74K
- Astellas Pharma US Inc$66K
- Therapeuticsmd, Inc.$26K
- Amgen$18K
- Pfizer$17K
- AMAG Pharmaceuticals, Inc.$17K
- plus $58K from 45 others
What the payments were for
- Consulting fees$50,56318%
- Speaking & faculty fees$183,02766%
- Grants$3,0001%
- Travel & lodging$24,7889%
- Food & beverage$13,9665%
- Education$3210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIJUVA$47,530
- NEXTSTELLIS$37,846
- Veozah$37,074
- Prolia$17,072
- UBRELVY$14,000
- INTRAROSA$10,856
- DUAVEE$10,096
- ANNOVERA$9,239
- Tymlos$3,010
- Lynkuet$1,932
- EVENITY$1,024
- Twirla$425
- MI CANCER SEEK$233
- NURTEC ODT$228
- DEXCOM G7 GSS (161)$126
- DEXCOM STELO GLUCOSE BIOSENSOR$126
- Korlym$125
- LINZESS$117
- IMVEXXY$111
- MAKENA$110
How this compares
$276,456 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 19 | $24,374 |
| EliquisApixaban | 18 | $15,221 |
| Praluent PenAlirocumab | 30 | $14,302 |
| Maraviroc | 12 | $13,657 |
| Repatha SureclickEvolocumab | 21 | $11,552 |
| MounjaroTirzepatide | 12 | $11,456 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $8,242 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 19 | $6,043 |
| PremarinEstrogens, Conjugated | 12 | $5,156 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $3,964 |
| Celecoxib | 33 | $2,580 |
| Rosuvastatin Calcium | 110 | $1,964 |
| Estradiol | 20 | $1,685 |
| Bupropion XlBupropion Hcl | 34 | $1,286 |
| Ezetimibe | 34 | $1,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Premarin | $17,450 | $26,42149 claims |
| Astellas Pharma US IncMyrbetriq | $65,955 | $24,37419 claims |
| Lilly USA, LLCMounjaro | $199 | $11,45612 claims |
| GSKShingrix | $13 | $3,96418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Antoinette PragalosCincinnati$27.8M
- Charles EgerCincinnati$8.7M
- Douglas LoganCincinnati$4.7M
- Leela VrishabhendraCincinnati$3.4M
- Traci TurnerCincinnati$645K
- Vincent MartinCincinnati$398K
- Mark EckmanCincinnati$255K
- Kay JohnsonCincinnati$184K
- Steven FolkerthBeavercreek$9.1M
- Vadim KoshkinCleveland$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.